Pablo Rendo

771 total citations
43 papers, 519 citations indexed

About

Pablo Rendo is a scholar working on Hematology, Genetics and Hepatology. According to data from OpenAlex, Pablo Rendo has authored 43 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 17 papers in Genetics and 7 papers in Hepatology. Recurrent topics in Pablo Rendo's work include Hemophilia Treatment and Research (21 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Platelet Disorders and Treatments (9 papers). Pablo Rendo is often cited by papers focused on Hemophilia Treatment and Research (21 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Platelet Disorders and Treatments (9 papers). Pablo Rendo collaborates with scholars based in United States, Argentina and Türkiye. Pablo Rendo's co-authors include José Luis Fernández, Lynne M. Smith, Joan Korth‐Bradley, Luis Viola, L. Rusen, Leonard A. Valentino, Ivo Elezović, Eduardo Abbate, Luis J. Montaner and Domingo Palmero and has published in prestigious journals such as Blood, PEDIATRICS and Medicine.

In The Last Decade

Pablo Rendo

38 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pablo Rendo United States	13	237	127	124	118	67	43	519
F. Ala Iran	13	237 1.0×	129 1.0×	80 0.6×	102 0.9×	49 0.7×	38	532
C. H. Tzeng Taiwan	13	180 0.8×	157 1.2×	41 0.3×	82 0.7×	53 0.8×	34	491
José María Morales Spain	12	171 0.7×	121 1.0×	103 0.8×	77 0.7×	10 0.1×	19	655
Abid Suddle United Kingdom	16	104 0.4×	261 2.1×	124 1.0×	409 3.5×	36 0.5×	58	697
N. L. C. Luban United States	14	362 1.5×	68 0.5×	146 1.2×	21 0.2×	40 0.6×	23	619
Nahıde Konuk Türkiye	12	347 1.5×	88 0.7×	51 0.4×	41 0.3×	110 1.6×	35	456
Dalton de Alencar Fischer Chamone Brazil	13	150 0.6×	85 0.7×	78 0.6×	44 0.4×	24 0.4×	38	367
Effie Liakopoulou United Kingdom	10	204 0.9×	110 0.9×	135 1.1×	14 0.1×	102 1.5×	21	518
Betty L. Goon United States	6	187 0.8×	301 2.4×	69 0.6×	362 3.1×	20 0.3×	8	551
M. Kerowgan Germany	10	200 0.8×	53 0.4×	61 0.5×	44 0.4×	19 0.3×	16	359

Countries citing papers authored by Pablo Rendo

Since Specialization

Citations

This map shows the geographic impact of Pablo Rendo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Rendo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Rendo more than expected).

Fields of papers citing papers by Pablo Rendo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Rendo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Rendo. The network helps show where Pablo Rendo may publish in the future.

Co-authorship network of co-authors of Pablo Rendo

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Rendo. A scholar is included among the top collaborators of Pablo Rendo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Rendo. Pablo Rendo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alavi, Asif, Lakshmanan Krishnamurti, Mehrdad Abedi, et al.. (2021). Preliminary Safety and Efficacy Results from Precizn-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD). Blood. 138(Supplement 1). 2930–2930. 22 indexed citations

Yang, Renchi, Yongqiang Zhao, Xuefeng Wang, et al.. (2020). <p>Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies</p>. Journal of Blood Medicine. Volume 11. 439–448. 2 indexed citations

Hua, Baolai, Runhui Wu, Feifei Sun, et al.. (2017). Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. Thrombosis and Haemostasis. 117(6). 1052–1057. 10 indexed citations

Korth‐Bradley, Joan, Pablo Rendo, Lynne M. Smith, & Carmen Altisent. (2016). Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. Clinical Therapeutics. 38(4). 936–944. 6 indexed citations

Nemes, László, Víctor Jiménez‐Yuste, L. Rusen, et al.. (2015). Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis. 114(10). 676–684. 6 indexed citations

Rendo, Pablo, et al.. (2015). Nonacog alfa. Blood Coagulation & Fibrinolysis. 26(8). 912–918. 5 indexed citations

Berntorp, Erik, David Keeling, Michael Makris, et al.. (2011). A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. Haemophilia. 18(4). 503–509. 11 indexed citations

Musso, Carlos G., et al.. (2004). Plasma erythropoietin levels in the oldest old. International Urology and Nephrology. 36(2). 259–262. 12 indexed citations

Fernández, José Luis, et al.. (2004). Influence of Hemodialysis Procedure on HCV RNA Detection in Serum and Peripheral Blood Mononuclear Cells. Renal Failure. 26(4). 369–373. 1 indexed citations

10.

Rendo, Pablo, et al.. (2002). Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clinical Nephrology. 57(5). 371–375. 22 indexed citations

11.

Rendo, Pablo, et al.. (2002). The Role of Transfusion-Transmitted Virus in Patients Undergoing Hemodialysis. Journal of Clinical Gastroenterology. 34(1). 86–88. 5 indexed citations

12.

Donato, Hugo, et al.. (2001). α-Interferon Therapy Induces Improvement of Platelet Counts in Children With Chronic Idiopathic Thrombocytopenic Purpura. The American journal of pediatric hematology/oncology. 23(9). 598–603. 8 indexed citations

13.

Rendo, Pablo, et al.. (2001). Massive plasmocytosis due to methimazole‐induced bone marrow toxicity. American Journal of Hematology. 67(4). 259–261. 18 indexed citations

14.

Donato, Hugo, Néstor Vain, Pablo Rendo, et al.. (2000). Effect of Early Versus Late Administration of Human Recombinant Erythropoietin on Transfusion Requirements in Premature Infants: Results of a Randomized, Placebo-Controlled, Multicenter Trial. PEDIATRICS. 105(5). 1066–1072. 71 indexed citations

15.

Fernández, José Luis, et al.. (2000). Hepatitis G Virus Infection in Hemodialysis Patients and Its Relationship with Hepatitis C Virus Infection. American Journal of Nephrology. 20(5). 380–384. 5 indexed citations

16.

Fernández, José Luis, et al.. (1998). Evidence of Hepatitis C Virus Passage Across Dialysis Membrane. The Nephron journals/Nephron journals. 80(2). 194–196. 28 indexed citations

17.

Fernández, José Luis, et al.. (1997). Virus de la hepatitis C en pacientes de una unidad de hemodiálisis. 9–22.

18.

Tanno, Hugo, et al.. (1995). Hepatitis C virus RNA and long‐term response to recombinant interferon‐α2b in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2(2). 97–102. 15 indexed citations

19.

Rozenblum, Ester, et al.. (1994). Interferon DNA Polymorphism in Chronic Leukemia. Leukemia & lymphoma. 13(1-2). 99–103. 3 indexed citations

20.

Rendo, Pablo, et al.. (1988). Tratamiento de la aplasia medular con globulina antilinfocitaria. Medicina-buenos Aires.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact